Price Targets

Business

Analysts Revise Lucid Group Outlook: What the New Price Target Signals for EV Investors

Wall Street analysts have issued a revised price target for Lucid Group (LCID), reflecting updated assessments of the electric vehicle maker's execution risks, funding runway, and demand trajectory. The shift underscores the evolving narrative around the company's ability to scale amid intense competition and macroeconomic headwinds.

Feb 2, 2026

Business

Markets Edge Higher Amid Earnings Anticipation; Oil Prices Slide on Geopolitical, Demand Concerns

U.S. stocks advanced cautiously Monday as investors braced for a wave of corporate earnings reports, while crude oil prices tumbled sharply. The focus remains on key tech results and evolving geopolitical developments affecting global trade and energy markets.

Feb 2, 2026

Business

Airgain's Revised Price Target Signals Shifting Market Sentiment

A recent adjustment to Airgain's price target by analysts reflects a broader reassessment of the wireless connectivity specialist's prospects, underscoring how evolving narratives, rather than single events, are reshaping investor views on the stock.

Feb 2, 2026

Business

Tesla's Shifting Narrative: How a Price Target Revision Reflects Deeper Questions About Its Future

A recent analyst price target update for Tesla, devoid of specific figures, has reignited debate over the core drivers of the stock's story. The focus is shifting from pure growth metrics to the underlying expectations and perceived risks surrounding its business model and long-term strategy.

Feb 2, 2026

Business

Analysts Recalibrate CareCloud Outlook: What's Behind the Revised Price Target?

A significant reset in CareCloud's (CCLD) price target by analysts is prompting a fresh look at the healthcare IT firm's risk-reward profile. This shift reflects evolving perspectives on the company's trajectory and market position. We examine the catalysts for this change and its implications for investors.

Feb 2, 2026

Business

STKS Price Target Cut After Q4 Revenue Shortfall, But Analysts See Long-Term Upside

Lake Street Capital maintains a Buy rating on The ONE Group Hospitality (STKS) despite lowering its price target, citing a solid finish in a tough market and a clear growth runway through 2026.

Feb 2, 2026

Business

Piper Sandler Trims Price Target for Black Diamond Therapeutics Amid Model Review, Despite Recent Clinical Wins

Analyst Piper Sandler has lowered its price target on Black Diamond Therapeutics (BDTX) while maintaining an Overweight rating, following a broad review of its biotech coverage. The adjustment comes even as the company recently reported encouraging Phase 2 data for its lead oncology drug candidate.

Feb 2, 2026

Business

Stifel Boosts Nurix Therapeutics Price Target to $35, Citing 2026 as Pivotal Year for Key Drug Candidate

Analysts at Stifel have raised their price target for Nurix Therapeutics (NRIX) to $35, maintaining a Buy rating ahead of anticipated 2026 clinical milestones for its lead asset, bexobrutinib. The move comes as Wells Fargo also adjusted its target, highlighting divergent near-term views but shared long-term optimism for the biotech firm.

Feb 2, 2026

Business

ABB Beats Earnings Expectations, Analysts Boost Price Target Amid Strong Growth Outlook

ABB's shares surged 10% following its annual results, with earnings per share exceeding forecasts. Analysts have raised their price target to CHF 60.30 and project accelerated revenue growth ahead of industry peers.

Feb 2, 2026

Business

Analysts Reassess RenaissanceRe: Price Target Reset Signals Shifting Risk Perceptions

A recent revision to RenaissanceRe Holdings' official price target has refocused market attention on the reinsurer, highlighting how evolving analyst assumptions—rather than a specific number—are reshaping the investment narrative around the stock.

Feb 2, 2026

Business

Ripple CTO Pours Cold Water on Lofty XRP Price Predictions Amid Market Downturn

Ripple's Chief Technology Officer, David Schwartz, has expressed skepticism about XRP reaching prices of $50 or $100, triggering a debate within the community as the cryptocurrency's value drops significantly this week.

Feb 2, 2026

Business

Analysts Revise Econocom Group Price Target, Signaling Shift in Market Sentiment

A fresh price target for Euronext Brussels-listed IT services firm Econocom Group has analysts and investors reassessing the company's trajectory. The update reflects evolving views on the company's strategic positioning and market conditions.

Feb 2, 2026

Business

Analysts Revise Haivision Systems Outlook: What the New Price Target Signals for Investors

A revised price target for Haivision Systems (TSX:HAI) is shifting the investment narrative, prompting a closer look at the video streaming technology firm's prospects amid evolving market conditions.

Jan 31, 2026

Business

Analysts Revise Outlook: What's Driving the New Price Target for Illinois Tool Works (ITW)

A revised price target for industrial conglomerate Illinois Tool Works has refocused investor attention, prompting a fresh assessment of the company's strategic positioning and market sentiment.

Jan 31, 2026

Business

Morgan Stanley Backs NIO with Overweight Rating, Citing Aggressive Delivery Targets and New Model Pipeline

Morgan Stanley reaffirms its Overweight rating on NIO Inc., maintaining a $7 price target. Analyst Tim Hsiao highlights the EV maker's plan for 40-50% annual delivery growth through 2026 and improved strategic focus following a meeting with founder William Li.

Jan 30, 2026

Business

USA Rare Earth Secures Major CHIPS Act Funding, Prompting Analyst Price Target Surge

USA Rare Earth Inc. (NASDAQ: USAR) sees its price target significantly raised by Canaccord Genuity and Benchmark following a landmark $1.6 billion commitment from the U.S. CHIPS Program, accelerating its plans to build a domestic rare earth supply chain.

Jan 30, 2026

Business

Occidental Petroleum's Rocky Road: Analysts Remain Cautious Despite Recent Oil-Price Tailwinds

While rising crude prices have lifted Occidental Petroleum's stock recently, a mixed earnings performance and a predominantly 'Hold' rating from Wall Street signal lingering skepticism about its near-term trajectory.

Jan 30, 2026

Business

BofA Trims JD.com Price Target Amid Slower Growth Forecasts, Joins DBS in Cautious Stance

Bank of America has modestly lowered its price target on JD.com, following a similar move by DBS, as analysts revise down revenue and profit estimates for the Chinese e-commerce giant, citing weaker consumer electronics demand and scaled-back subsidy programs.

Jan 30, 2026

Business

Guggenheim More Than Doubles Erasca Price Target to $12 on Clinical Progress and Pipeline Updates

Erasca Inc. (ERAS) sees its price target raised from $5 to $12 by Guggenheim, following promising clinical data for its lead oncology candidates and updated financial models. The move comes amid a series of positive analyst revisions for the clinical-stage biopharma firm.

Jan 30, 2026

Business

LifeSci Capital Boosts Price Target on Olema Pharmaceuticals, Citing Promising Breast Cancer Drug Pipeline

LifeSci Capital reaffirms its Buy rating on Olema Pharmaceuticals (OLMA) and raises its price target to $45, following bullish analyst sentiment on the company's lead drug candidate, Palazestrant, for ER+/HER2- breast cancer.

Jan 30, 2026